FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985058098> ?p ?o ?g. }

• W2985058098 abstract "Abstract Background Chemotherapy-induced anemia (CIA) contributes to poor patient outcomes and increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA involves intravenous iron, red blood cell (RBC) transfusions, and erythrocyte stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is independently associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs and whether or not this risk is consistent across gender and age. Methods A retrospective study analyzed 13,334 patients with various malignancies who developed CIA between 1998-2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after controlling for RBC and ESA intervention (within 90 days after CIA diagnosis). Data was then stratified by gender and age ( Results Among the 13,334 patients with CIA, 2,620 (19.7%) developed a VTE. Despite stratification by gender, VTE risk following RBC transfusion was approximately four-fold the VTE risk following ESA administration (Table). Among patients with CIA who were Table: 106P . Treatment and outcomes within 90 days following CIA diagnosis No treatment RBC only ESA only RBC and ESA Patients with VTE (All Patients) 2028 (10,948) 538 (1,892) 42 (368) 12 (126) 18.5% 28.4% (HR = 2.18, 95% CI 1.98-2.39, p  11.4% (HR = 0.55, 95% CI 0.42-0.72, p  9.5% Men with VTE (All male patients) 970 (5428) 269 (917) 21 (182) 5 (61) 17.9% 29.3% (HR = 2.33, 95% CI (2.04-2.67, p  11.5% (HR = 0.55, 95% CI (0.37-0.81, p = 0.002) 8.3% Women with VTE (All female patients) 1058 (5519) 269 (975) 21 (186) 7 (65) 19.2% 27.6% (HR = 2.04, 95% CI (1.79-2.33), p  11.3% (HR = 0.56, 95% CI (0.38-0.81), p = 0.002) 10.8% Conclusions Among patients with CIA, there is an approximate four-fold increased risk of VTE development with RBC transfusion as compared with ESA administration. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest." @default.
• W2985058098 created "2019-11-22" @default.
• W2985058098 creator A5001143622 @default.
• W2985058098 creator A5012507181 @default.
• W2985058098 creator A5015276591 @default.
• W2985058098 creator A5052533022 @default.
• W2985058098 creator A5066025840 @default.
• W2985058098 date "2019-11-01" @default.
• W2985058098 modified "2023-09-28" @default.
• W2985058098 title "A 19-year retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration" @default.
• W2985058098 doi "https://doi.org/10.1093/annonc/mdz413.110" @default.
• W2985058098 hasPublicationYear "2019" @default.
• W2985058098 type Work @default.
• W2985058098 sameAs 2985058098 @default.
• W2985058098 citedByCount "0" @default.
• W2985058098 crossrefType "journal-article" @default.
• W2985058098 hasAuthorship W2985058098A5001143622 @default.
• W2985058098 hasAuthorship W2985058098A5012507181 @default.
• W2985058098 hasAuthorship W2985058098A5015276591 @default.
• W2985058098 hasAuthorship W2985058098A5052533022 @default.
• W2985058098 hasAuthorship W2985058098A5066025840 @default.
• W2985058098 hasBestOaLocation W29850580981 @default.
• W2985058098 hasConcept C126322002 @default.
• W2985058098 hasConcept C141071460 @default.
• W2985058098 hasConcept C167135981 @default.
• W2985058098 hasConcept C207103383 @default.
• W2985058098 hasConcept C2776694085 @default.
• W2985058098 hasConcept C2778248108 @default.
• W2985058098 hasConcept C2780014101 @default.
• W2985058098 hasConcept C44249647 @default.
• W2985058098 hasConcept C50382708 @default.
• W2985058098 hasConcept C71924100 @default.
• W2985058098 hasConceptScore W2985058098C126322002 @default.
• W2985058098 hasConceptScore W2985058098C141071460 @default.
• W2985058098 hasConceptScore W2985058098C167135981 @default.
• W2985058098 hasConceptScore W2985058098C207103383 @default.
• W2985058098 hasConceptScore W2985058098C2776694085 @default.
• W2985058098 hasConceptScore W2985058098C2778248108 @default.
• W2985058098 hasConceptScore W2985058098C2780014101 @default.
• W2985058098 hasConceptScore W2985058098C44249647 @default.
• W2985058098 hasConceptScore W2985058098C50382708 @default.
• W2985058098 hasConceptScore W2985058098C71924100 @default.
• W2985058098 hasLocation W29850580981 @default.
• W2985058098 hasOpenAccess W2985058098 @default.
• W2985058098 hasPrimaryLocation W29850580981 @default.
• W2985058098 hasRelatedWork W1605060438 @default.
• W2985058098 hasRelatedWork W2033846924 @default.
• W2985058098 hasRelatedWork W2063240991 @default.
• W2985058098 hasRelatedWork W2157972818 @default.
• W2985058098 hasRelatedWork W2171851177 @default.
• W2985058098 hasRelatedWork W2331549604 @default.
• W2985058098 hasRelatedWork W2419299251 @default.
• W2985058098 hasRelatedWork W2526787604 @default.
• W2985058098 hasRelatedWork W2606274259 @default.
• W2985058098 hasRelatedWork W2893262872 @default.
• W2985058098 hasRelatedWork W2910060757 @default.
• W2985058098 hasRelatedWork W2918959983 @default.
• W2985058098 hasRelatedWork W2981959189 @default.
• W2985058098 hasRelatedWork W2993707155 @default.
• W2985058098 hasRelatedWork W2999224097 @default.
• W2985058098 hasRelatedWork W3089332811 @default.
• W2985058098 hasRelatedWork W3166067762 @default.
• W2985058098 hasRelatedWork W3169583279 @default.
• W2985058098 hasRelatedWork W3209289204 @default.
• W2985058098 hasRelatedWork W872580702 @default.
• W2985058098 isParatext "false" @default.
• W2985058098 isRetracted "false" @default.
• W2985058098 magId "2985058098" @default.
• W2985058098 workType "article" @default.